Grand Opening of APAO 2026

Centered on the theme of Innovation, Collaboration and Translation, the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO 2026) was solemnly held in Hong Kong, China from February 5 to 8, 2026. As the largest and most influential ophthalmology event in the Asia-Pacific region, this congress successfully built a high-level dialogue platform bringing together top global experts, clinicians and industry leaders.

This congress not only provided a forward-looking and comprehensive academic agenda that deeply integrated global wisdom, but also dedicated itself to inspiring idea exchanges among leading global experts and scholars, continuously driving the overall progress and innovation of the ophthalmology field.

As a professional domestic ophthalmic device company, Brisight Nord attracted numerous international attendees at the congress with its open, orderly and concise booth design, and facilitated multiple in-depth professional exchanges.

Core Exhibits

In the core surgical instrument exhibition area, Brisight Nord highlighted its domestic vitrectomy solution. The vitrectomy probe series exhibited by the company has obtained the medical device registration certificate from the National Medical Products Administration (NMPA Registration No.: 20243161676). Its scope of application, safety and effectiveness have met relevant standards upon registration review, and it has been clinically applied in many well-known Class III Grade A hospitals in China.

Cutting-edge Exploration

The registration process of Brisight Nord’s phaco-vitrectomy integrated system is actively underway. At this APAO Congress, the technical roadmap and progress of this integrated surgical device aroused extensive interest and discussions among international peers.

Looking Forward

The APAO Congress is not only a showcase of academic achievements in Asia-Pacific ophthalmology, but also a convergence point for global innovative forces. With solid product strength and cutting-edge innovative vision, Brisight Nord has demonstrated the R&D capability and market potential of Chinese ophthalmic device brands on the international stage.

From domestic substitution to innovation leadership, Made in China is leaving an increasingly profound mark in the global ophthalmology field.